The Impact of Dietary Phosphorus on Postprandial Metabolic Responses and Markers of Metabolic Health (DPMPG)

November 3, 2026 updated by: Omar Obeid, American University of Beirut Medical Center

The Effect of Dietary Phosphorus Manipulation on Postprandial Glycemia

To examine the effects of dietary phosphorus availability, including supplementation and restriction conditions, on postprandial glucose responses in healthy adults.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Two randomized, controlled, crossover experiments were conducted in healthy adults. Experiment 1 evaluated a refined carbohydrate test meal with phosphorus supplementation (~684 mg potassium phosphate) versus placebo. Experiment 2 assessed a dairy-based test meal under normal phosphorus availability versus reduced bioavailability using the phosphate-binding agent sevelamer carbonate. Each experiment followed a 10-day protocol comprising two intervention phases separated by a washout period. Within each phase, participants completed two identical test days per condition. Postprandial glucose was continuously monitored for 180 minutes. Primary outcomes included peak glucose, incremental glucose response (ΔBG), and incremental area under the curve (iAUC). Secondary outcomes included subjective appetite ratings assessed using validated visual analogue scale (VAS) questionnaires

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Lebanon
      • Beirut, Lebanon
        • American University of Beirut

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 64 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

• Non diabetic

Exclusion Criteria:

  • pregnancy or lactation
  • diagnosis of diabetes
  • recent weight loss (>3% within 3 months); psychiatric illness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: refined low phosphorus carbohydrate meal

High-carbohydrate meal with low phosphorus content
Dietary supplement: high carbohydrate meal with phosphorus supplementation

high-carbohydrate meal with 684 mg of phosphorus supplement
Active Comparator: Full fat powdered milk meal

The meal or drink was composed of full-fat powdered milk meal which is naturally high in phosphorus
Drug: Full fat milk meal with phosphate binder

Full fat dairy milk meal with 800 mg sevelamer carbonate (Renvela®)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
postprandial glucose
Time Frame: 10 days

Monitoring glucose concentration
10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective appetite score
Time Frame: 180 minutes

changes in appetite scores between 0 -10 points
180 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

American University of Beirut Medical Center

Collaborators

University of Nottingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 17, 2023

Primary Completion (Actual)

October 1, 2025

Study Completion (Actual)

April 1, 2026

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

November 3, 2026

First Posted (Actual)

November 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 6, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BIO-2022-0015
  • BIO-2022-0015 (Other Identifier: American University of Beirut)
  • FMHS 392-1121 (Other Identifier: University of Nottingham)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe